Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502824 · ClinicalTrials.gov registry record · NA
PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
A NA study, sponsored by Organogenesis.
- Terminated
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT03502824: Clinical Trial NA study, sponsored by Organogenesis.
NCT03502824 is a NA study that was terminated before completion, run by Organogenesis. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03502824, a NA study, was terminated before completion, sponsored by Organogenesis.
- TERMINATED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a prospective, multi-center, randomized, controlled clinical study Of PuraPly® AM and standard of care (SOC) compared to SOC alone for the management of Stage II-IV pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.
Primary Outcome
As measured from change in size from baseline
Interventions
- DEVICE PuraPly® Antimicrobial Wound Matrix
- OTHER SOC for Pressure Ulcers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2021-09-15 |
| Phase | NA |
Why NCT03502824 stopped before completion
NCT03502824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which PuraPly® Antimicrobial Wound Matrix is the first listed.
NCT03502824 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03502824 about?
NCT03502824 is a clinical study titled "PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.". This is a prospective, multi-center, randomized, controlled clinical study Of PuraPly® AM and standard of care (SOC) compared to SOC alone for the management of Stage II-IV pressure ulcers located in the gluteal, ischial, hip, sacral, coccygeal, and trochanteric, malleolus, or heel area.
What is the current status of trial NCT03502824?
This trial is currently terminated. It is a NA study. The enrollment target is 40 participants. The study started on 2018-05-01. Estimated completion is 2021-09-15.
What interventions are being tested in trial NCT03502824?
The interventions under investigation include: PuraPly® Antimicrobial Wound Matrix (DEVICE), SOC for Pressure Ulcers (OTHER).
Who is sponsoring clinical trial NCT03502824?
This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03502824's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI